Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC4TARGET Asciminib in CML-CP or CML-AP with T315I after ponatinib failure/ineligibility
2024-516049-38-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of asciminib in chronic myelogenous leukemia (CML) and chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Rate of BCR::ABL1 IS ≤ 1% (MR2) at 12 months. Planned start Nov 2024; status: authorised.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on 2024-516049-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516049-38-00.